After providing investors with a number of clinical updates, Novavax (NASDAQ: NVAX), a clinical-stage biotech focused on vaccines, saw its shares decline 24% as of 11:45 a.m. EDT on Tuesday.
Here’s a review of the key highlights from the company’s big announcement:
First, Novavax said that its phase 3 Prepare trial — which is studying its respiratory syncytial virus candidate, RSV F Vaccine, in infants via maternal immunization — continues to progress. The company said that it is actively enrolling patients at 80 sites in 11 countries.